BRNS insider transaction filings
Barinthus Biotherapeutics plc. — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-11. Screen BRNS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 9 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 50.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Enright William — Chief Executive Officer, Director | 1 | — | — | 7 |
| Morgon Pierre A. — Director | 1 | — | — | 7 |
| Wright Robin — Director | 1 | — | — | 7 |
| DAWES KAREN A — Director | 1 | — | — | 6 |
| Hammacher Alex — Director | 1 | — | — | 6 |
| Phillips Anne M. — Director | 1 | — | — | 6 |
| Scheeren Joseph — Director | 1 | — | — | 6 |
| Hooftman Leon — Chief Medical Officer | 1 | — | — | 4 |
| Oxford Science Enterprises plc | 1 | — | — | 1 |
Recent Form 4 filings — Barinthus Biotherapeutics plc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4/A | Oxford Science Enterprises plc | Code (U): 8,797,770 @ $0.11 | EDGAR |
| 2026-09-09 | 4 | Enright William — Chief Executive Officer, Director | Disposition to issuer (D): 728,454 · Disposition to issuer (D): 514,923 · Disposition to issuer (D): 176,130 (derivative) @ $0 · Disposition to issuer (D): 359,605 (derivative) @ $0 · Disposition to issuer (D): 440,000 (derivative) @ $0 · Disposition to issuer (D): 443,981 (derivative) @ $0 · +1 more | EDGAR |
| 2026-09-09 | 4 | Hammacher Alex — Director | Disposition to issuer (D): 3,000 · Disposition to issuer (D): 34,328 (derivative) @ $0 · Disposition to issuer (D): 18,604 (derivative) @ $0 · Disposition to issuer (D): 19,197 (derivative) @ $0 · Disposition to issuer (D): 19,516 (derivative) @ $0 · Disposition to issuer (D): 20,174 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Hooftman Leon — Chief Medical Officer | Grant/award (A): 361,530 · Disposition to issuer (D): 361,530 · Disposition to issuer (D): 195,166 (derivative) @ $0 · Disposition to issuer (D): 140,000 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Morgon Pierre A. — Director | Disposition to issuer (D): 10,506 · Disposition to issuer (D): 20,394 (derivative) @ $0 · Disposition to issuer (D): 34,328 (derivative) @ $0 · Disposition to issuer (D): 18,604 (derivative) @ $0 · Disposition to issuer (D): 19,197 (derivative) @ $0 · Disposition to issuer (D): 19,516 (derivative) @ $0 · +1 more | EDGAR |
| 2026-09-09 | 4 | Phillips Anne M. — Director | Disposition to issuer (D): 3,000 · Disposition to issuer (D): 34,328 (derivative) @ $0 · Disposition to issuer (D): 18,604 (derivative) @ $0 · Disposition to issuer (D): 19,197 (derivative) @ $0 · Disposition to issuer (D): 19,516 (derivative) @ $0 · Disposition to issuer (D): 20,174 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Scheeren Joseph — Director | Disposition to issuer (D): 23,000 · Disposition to issuer (D): 34,328 (derivative) @ $0 · Disposition to issuer (D): 18,604 (derivative) @ $0 · Disposition to issuer (D): 19,197 (derivative) @ $0 · Disposition to issuer (D): 19,516 (derivative) @ $0 · Disposition to issuer (D): 20,174 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Wright Robin — Director | Disposition to issuer (D): 48,256 · Disposition to issuer (D): 20,394 (derivative) @ $0 · Disposition to issuer (D): 34,328 (derivative) @ $0 · Disposition to issuer (D): 18,604 (derivative) @ $0 · Disposition to issuer (D): 19,197 (derivative) @ $0 · Disposition to issuer (D): 19,516 (derivative) @ $0 · +1 more | EDGAR |
| 2026-09-09 | 4 | DAWES KAREN A — Director | Disposition to issuer (D): 1,700 · Disposition to issuer (D): 34,328 (derivative) @ $0 · Disposition to issuer (D): 18,604 (derivative) @ $0 · Disposition to issuer (D): 19,197 (derivative) @ $0 · Disposition to issuer (D): 19,516 (derivative) @ $0 · Disposition to issuer (D): 20,174 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Hammacher Alex — Director | Grant/award (A): 20,174 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Wright Robin — Director | Grant/award (A): 20,174 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Morgon Pierre A. — Director | Grant/award (A): 20,174 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Scheeren Joseph — Director | Grant/award (A): 20,174 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Phillips Anne M. — Director | Grant/award (A): 20,174 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | DAWES KAREN A — Director | Grant/award (A): 20,174 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Brown Gemma — Chief Financial Officer | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Griffiths Graham — Chief Business Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Hooftman Leon — Chief Medical Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Enright William — Chief Executive Officer, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Hooftman Leon — Chief Medical Officer | Grant/award (A): 195,166 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Scheeren Joseph — Director | Grant/award (A): 19,516 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Hammacher Alex — Director | Grant/award (A): 19,516 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Morgon Pierre A. — Director | Grant/award (A): 19,516 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Wright Robin — Director | Grant/award (A): 19,516 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Phillips Anne M. — Director | Grant/award (A): 19,516 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | DAWES KAREN A — Director | Grant/award (A): 19,516 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Pelletier Nadege — Chief Scientific Officer | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Griffiths Graham — Chief Business Officer | Grant/award (A): 96,500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Brown Gemma — Chief Financial Officer | Grant/award (A): 193,000 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Enright William — Chief Executive Officer, Director | Grant/award (A): 443,981 (derivative) @ $0 | EDGAR |
Recent 8-K events — Barinthus Biotherapeutics plc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-09 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-01 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events | EDGAR |
| 2026-08-25 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-05-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BRNS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →